Back to News
Market Impact: 0.2
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral from Sell
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 8, 2026, Goldman Sachs upgraded Rocket Pharmaceuticals from Sell to Neutral, following its March 2, 2026 decision to maintain a Sell rating. The article provides no price target, rationale, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
RCKT0.40
More News
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
- Why is argenx stock rallying today?
- Goldman Sachs lowers Pepsico stock price target on growth outlook
- Goldman Sachs reiterates Buy on Dell stock amid AI supply constraints
- Cramer’s week ahead: Earnings kick off as banks and chipmakers face big tests
- Nasdaq, SPX Look to End Record-Filled Week With Gains